BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.
http://ow.ly/zlCi
...
Your friends are reading OrthoStreams daily - Are you ?
Unlock your access to full rich article, trends, hot startups, market reports and your daily newsletter.
The Orthopedics Industry 
